Something went wrong

We encountered an unexpected error, we encourage you to try again later.

We're here to help

Should you have additional questions please contact PfizerPro customer service.

Representatives are available:
Monday-Friday 8:00am to 9:00pm Eastern time

Call 1 (800) 505-4426


PP-UNP-USA-5796

Order samples Unable to confirm your eligibility

Unfortunately, your registration is incomplete and we are unable to confirm your eligibility for sample ordering.

To gain access please enter your professional information within your account.

Open your account We're here to help

Should you need further support updating your account information, please contact PfizerPro customer service.

Representatives are available:
Monday-Friday 8:00am to 9:00pm Eastern time

Call 1 (800) 505-4426


​​​​​​​PP-UNP-USA-5796

Order samples

Thank you for expressing interest in Pfizer samples. Currently there are no samples available to order. Samples renew periodically, we encourage you to check back soon.

 We're here to help

Should you have additional questions please contact PfizerPro customer service.

Representatives are available:
Monday-Friday 8:00am to 9:00pm Eastern time

Call 1 (800) 505-4426


​​​​​​​PP-UNP-USA-5796

Order samples

All samples available online to you are included below. Availability is updated periodically.

PP-UNP-USA-5796

Important Notice

Savings cards will be shipped with Product Samples, if applicable.

Signature

Use your mouse, finger, or stylus to sign below.

Legal Notice

I certify that I am a licensed prescriber, eligible to request and receive the drug samples listed in the quantities indicated. I am also confirming that these samples will be used exclusively for the medical treatment of my patients in conformity with all relevant state and/or local prescribing and dispensing requirements. My signature will also serve as confirmation of my receipt of these medications, if delivered by a company representative, or my intention to acknowledge them upon delivery to my medical office if shipped via common carrier. I understand that these samples cannot be sold, traded, bartered returned for credit or utilized to seek or obtain reimbursement.

Your order has been placed

We have received your order and are getting it ready

More to explore Patient assistance

Download available co-pay cards and patient savings offers across select Pfizer products.

Explore patient assistance Loading Vaccines

Find out more about the diseases, treatments and prevention methods that are impacted by our Pfizer Vaccine portfolio.

Explore Vaccines Loading

PP-UNP-USA-5796

Leave ordering?

Changes you have made will not be saved.

This site is intended for U.S. healthcare professionals.

Visit Pfizer Medical

Menu

Close

Sign InLog OutTherapy AreasProductsOrder VaccinesOrder SamplesOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysPfizer Dermatology Patient AccessExplore ContentEventsMaterialsVideosContact

Menu

Close

HomeCDC RecommendationAbout RSVAbout ABRYSVO

About ABRYSVO

Efficacy ProfileImmunobridgingSafety ProfilePatient ProfilesDosing, Storage, & ReconstitutionReal-World EvidenceOrder ABRYSVO

Order ABRYSVO

Order ABRYSVORefer ABRYSVOAccess & Support

Access & Support

Health Plan CoverageRequest a RepVaccine LocatorMaterialsVideos
Prescribing InformationIndicationsPatient SiteMaternal
Help provide protection against RSV with ABRYSVO®, a Pfizer vaccine1

Don’t wait—discuss vaccination with ABRYSVO today*

 ReferencesRSV vaccination should be given only to adults who have not yet received a dose of RSV vaccine. Providers can give the RSV vaccine year-round. However, RSV vaccination will have the most benefit if given in late summer or early fall before RSV usually starts to spread in the community.2Patient attestation is sufficient evidence of the presence of a risk factor. Vaccinators should not deny RSV vaccination to a person because of lack of medical documentation. For a complete list of chronic medical conditions associated with increased risk, visit the Centers for Disease Control and Prevention website.2 Powerful protection against RSV in adults 60 years and older‡

86% vaccine efficacy against RSV-LRTD with ≥3 symptoms
(96.66% CI, 32.0%-98.7%)1

67% vaccine efficacy against RSV-LRTD with ≥2 symptoms
(96.66% CI, 28.8%-85.8%)1

 View Efficacy Data

‡Primary Analysis: The median duration of efficacy follow-up was 7 months. Evaluable efficacy population: ABRYSVO, n=16,306; placebo, n=16,308.1

 Rates of systemic AEs similar to placebo in adults aged 60 years and olderSimilar rate of systemic events reported between ABRYSVO (27%) and placebo (26%) groups3

The most commonly reported solicited local and systemic adverse reactions in individuals aged 60 and older (≥10%) with ABRYSVO were fatigue (15.7%), headache (12.9%), pain at the injection site (10.6%), and muscle pain (10.2%)1 View Safety Data LoadingLearn About the Effectiveness of ABRYSVO in a Real-World Study in Adults 60+The effectiveness of ABRYSVO was evaluated in a real-world study with over 5,000 adults aged 60 years and older4
Learn More About the RWE Study
Vaccinate Your Eligible Patients Aged 50 Years and Older Today with ABRYSVO2
Vaccine Locator Tool
LoadingApproved for 3 Vulnerable Populations1

ABRYSVO: 1 vaccine approved to prevent RSV-LRTD in1: 

  • Adults aged 18-59 at increased risk  
  • Adults aged 60+
  • Infants from birth through 6 months of age via maternal immunization (given at 32-36 weeks of gestation) 

Learn more about the maternal indication

LoadingReconstitution with ABRYSVOABRYSVO offers an all-in-one solution for needle-free§ 
reconstitution1



Learn more about ABRYSVO®ACT-O-VIAL®ABRYSVO offers an all-in-one solution for needle-free§ reconstitution1



Learn more about ABRYSVO®ACT-O-VIAL®§Needle required for intramuscular injection is not included.1LoadingResources and Access Info

Get the support you need and learn more about costs and coverage

LoadingAE=adverse event; CDC=Centers for Disease Control and Prevention; CI=confidence interval; LRTD=lower respiratory tract disease; RSV=respiratory syncytial virus; RWE=real-world evidence.
Stay Informed
 Receive Updates About ABRYSVO    Register NowLoading Request a Pfizer Sales Representative  Connect NowLoadingView ResourcesLoading
Stay Informed
 Receive Updates About ABRYSVO    Register NowLoading Request a Pfizer Sales Representative  Connect NowLoadingView ResourcesLoading
References:ABRYSVO (Respiratory Syncytial Virus Vaccine) Prescribing Information. Pfizer Inc; June 2025. Centers for Disease Control and Prevention. RSV vaccine guidance for adults. Updated July 8, 2025. Accessed July 10, 2025. https://www.cdc.gov/rsv/hcp/vaccine-clinical-guidance/older-adults.html

Walsh EE, Pérez Marc G, Zareba AM, et al; for the RENOIR Clinical Trial Group. Efficacy and safety of a bivalent RSV prefusion F vaccine in older adults. N EnglJ Med. 2023;388(16):1465-1477.

Tartof SY, Aliabadi N, Goodwin G, et al. Estimated vaccine effectiveness for respiratory syncytial virus–related lower respiratory tract disease. JAMA Netw Open. 2024;7(12):e2450832

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2025 Pfizer Inc. All rights reserved.

PP-A1G-USA-2410
IndicationsABRYSVO is a vaccine indicated for:
 
  • active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older
  • active immunization of pregnant individuals at 32 through 36 weeks gestational age for the prevention of LRTD and severe LRTD caused by RSV in infants from birth through 6 months of age
  • active immunization for the prevention of LRTD caused by RSV in individuals 18 through 59 years of age who are at increased risk for LRTD caused by RSV
Please click here for full Prescribing Information.
Important Safety Information
  • Do not administer ABRYSVO to individuals with a history of a severe allergic reaction (e.g., anaphylaxis) to any component of ABRYSVO
  • The results of a postmarketing observational study suggest an increased risk of Guillain-Barré syndrome during the 42 days following vaccination with ABRYSVO
  • A numerical imbalance in preterm births was observed compared to placebo in 2 clinical studies. Data are insufficient to establish or exclude a causal relationship between preterm birth and ABRYSVO. To avoid potential risk of preterm birth with use of ABRYSVO before 32 weeks of gestation, administer to pregnant individuals at 32 through 36 weeks gestational age
  • Appropriate medical treatment must be available in case of an anaphylactic reaction
  • Syncope (fainting) may occur with administration of injectable vaccines, including ABRYSVO. Procedures should be in place to avoid injury from fainting
  • Immunocompromised individuals, including those receiving immunosuppressive therapy, may have a diminished immune response to ABRYSVO
  • Vaccination with ABRYSVO may not protect all recipients
  • In clinical trials with adults aged 60+, the most commonly reported (≥10%) adverse reactions
were fatigue (15.7%), headache (12.9%), pain at the injection site (10.6%), and muscle pain (10.2%)
  • In clinical trials with adults aged 18-59, the most commonly reported (≥10%) adverse reactions were pain at the injection site (35.3%), muscle pain (24.4%), joint pain (12.4%), and nausea (11.8%)
  • In clinical trials with pregnant individuals, the most commonly reported (≥10%) adverse reactions
were pain at the injection site (40.6%), headache (31.0%), muscle pain (26.5%), and nausea (20.0%)
  • In clinical trials with infants born to pregnant individuals, low birth weight (5.1% ABRYSVO vs 4.3% placebo) and neonatal jaundice (7.3% ABRYSVO vs 6.9% placebo) were observed
Individuals who received ABRYSVO during pregnancy are encouraged to contact 1-800-616-3791 to enroll in a Pregnancy Exposure Registry.

Patients should always ask their healthcare providers for medical advice about adverse events. You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit http://www.vaers.hhs.gov or call 1-800-822-7967.

Please see full Prescribing Information for ABRYSVO.IndicationsABRYSVO is a vaccine indicated for:
  • active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older
     
  • active immunization of pregnant individuals at 32 through 36 weeks gestational age for the prevention of LRTD and severe LRTD caused by RSV in infants from birth through 6 months of age
     
  • active immunization for the prevention of LRTD caused by RSV in individuals 18 through 59 years of age who are at increased risk for LRTD caused by RSV
You are now leaving PfizerPro
You are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer.

PP-MCL-USA-0367